New shot aims to knock down stubborn hepatitis b virus
NCT ID NCT02065336
Summary
This study tested whether adding a new investigational drug called ARC-520 to the standard Hepatitis B medication entecavir could better control the virus. It involved 58 adults with chronic Hepatitis B and aimed to see if the combination could safely and significantly reduce levels of a key viral protein in the blood. The trial was designed to find the right dose and understand how the body processes the new medicine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Pokfulam, Hong Kong
-
Research Site 2
Shatin, Hong Kong
Conditions
Explore the condition pages connected to this study.